Optics.org
Optics.org
daily coverage of the optics & photonics industry and the markets that it serves
News
Menu
Applications

Lumedica makes debut with low-cost OCT scanner

01 Feb 2017

Durham, North Carolina, startup aiming to sell systems at a price of $10,000.

The BiOS Expo, part of SPIE's Photonics West event taking place this week in San Francisco, witnessed the unveiling of a new low-cost optical coherence tomography (OCT) scanner that developer Lumedica believes could dramatically extend the impact of the imaging technology for eye health.

Founded in Durham, North Carolina, by an experienced team of engineers including chief scientist Adam Wax from Duke University, Lumedica’s debut scanner is priced at $10,000 – in a sector where entry-level equipment typically costs at least $35,000.

Bottom-up design
Wax explains that the low cost is achieved by using optical components already manufactured in volume for cell phones, coupled with a streamlined manufacturing process that reduces build time to a few man-hours.

“We designed it from the bottom up,” Wax said, showing off the shoebox-sized equipment at the Lumedica stand. Off-the-shelf components in the system helping to cut costs include an 840 nm superluminescent light-emitting diode (SLED) and a liquid lens.

Originally set up in 2014 but in stealth mode until recently, the company has won small business innovation research (SBIR) funding to aid the development process, but is now engaged in a more significant seed funding round. VP of marketing Scott Whitney said that Lumedica would be aiming to raise around $500,000 to further reduce the size of the scanner equipment so that the “2.0” version would be truly portable.

Startup Challenge
While OCT has proved itself to be an extremely effective diagnostic tool for ophthalmology, the cost of current systems means that it tends to be restricted to large, regional health centers. If proved to be effective, much cheaper systems could become widely deployed in “red flag” diagnostics – for example by optometrists – to pick up early signs of diseases like glaucoma and diabetic retinopathy.

Wax says that although important regulatory hurdles still need to be cleared, the technology has the potential to leverage the existing wealth of clinical evidence for OCT built up over the past couple of decades.

He represented Lumedica at the SPIE Startup Challenge semi-finals, which took place at San Francisco's Park Central Hotel January 31, and progressed to the final from the technology track dedicated to life science technologies.

The Startup Challenge final, where the winner will walk away with $10,000 in cash from founding sponsor Jenoptik and $5000 in equipment, takes place February 1 at the Moscone Center. The Startup Challenge supporting sponsors are Edmund Optics, Open Photonics, Trumpf and the US National Science Foundation.

NUBURU IncSynopsys, Optical Solutions GroupDiffraction InternationalEdmund OpticsBristol Instruments, Inc.Omicron-Laserage Laserprodukte GmbHSchaefter und Kirchhoff GmbH
Copyright © 2019 SPIE EuropeDesigned by Kestrel Web Services